EGFR mutation, as one of the most common driving genes in NSCLC, has an incidence rate of approximately 50% in lung adenocarcinoma patients in China [1]. In recent years, EGFR-TKI has brought good survival prognosis to EGFR mutation positive patients, but there are still some patients who are not sensitive to EGFR-TKI treatment in clinical practice.

EGFR Ex20ins mutation is the third largest mutation in EGFR. In the Chinese population, EGFR Ex20ins mutation accounts for 4-12% of EGFR gene mutations and 3% of NSCLC. The EGFR EX20ins mutation has the characteristics of high heterogeneity, refractory nature, poor prognosis, and high malignancy. In recent years, more and more new drugs targeting this mutation have emerged, but the recommendation of targeted therapy in first-line treatment still lacks evidence. NSCLC carrying EGFR Ex20ins urgently needs new therapies. At present, several small molecule drugs have entered the clinical trial stage. Taking this opportunity, Professor Wang Jie from the Cancer Hospital of the Chinese Academy of Medical Sciences is invited by [Tumor Information] to interpret the current clinical treatment status and the most important breakthrough progress in first-line treatment of EGFR EX20ins mutant NSCLC, in order to inspire clinical practice.